Regeneron Pharma (REGN) PT Raised to $700 at Canaccord Genuity on $450M BARDA COVID-19 Grant
Tweet Send to a Friend
Canaccord Genuity analyst John Newman raised the price target on Regeneron Pharma (NASDAQ: REGN) to $700.00 (from $660.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
